Table II.
Dose, trough concentration and dose-adjusted trough concentration of tacrolimus in relation to CYP 3A5 genotype up to 24 months after transplantation.
| Periods after transplantation | |||
|---|---|---|---|
| Variable | 6 months | 12 months | 24 months |
| Dose (mg/kg/day) | |||
| CYP 3A5*1/*3 | 0.09 (0.08–0.15)a | 0.08 (0.05–0.09)a | 0.07 (0.04–0.10) |
| CYP 3A5*3/*3 | 0.06 (0.04–0.08) | 0.05 (0.04–0.07) | 0.04 (0.03–0.06) |
| C0 (ng/ml) | |||
| CYP 3A5*1/*3 | 7.60 (6.40–9.10) | 7.10 (5.50–7.30) | 5.10 (4.60–7.50) |
| CYP 3A5*3/*3 | 7.30 (6.20–8.70) | 7.60 (5.70–8.60) | 6.50 (5.70–7.80) |
| C0/D [(ng/ml)/(mg/kg/day)] | |||
| CYP 3A5*1/*3 | 52.31 (49.82–103.13)a | 81.59 (64.80–121.50)a | 115.24 (75.38–151.30)a |
| CYP 3A5*3/*3 | 122.19 (88.92–172.36) | 135.88 (93.97–216.45) | 150.75 (115.58–227.52) |
Data are expressed as median (interquatile range). C0, tacrolimus trough concentration; C0/D, dose-adjusted trough concentration of tacrolimus.
a
P<0.05 vs. CYP 3A5*3/*3.